Interrogating not just the target but how it interacts with its native ecosystem

At OMass Therapeutics, we are identifying new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry. We distil biology to its essential elements – physical interactions within a native ecosystem – to deliver cell-system fidelity and cell-free precision.

Read More About Our Science

Focus on patients with immunological and orphan diseases

OMass is identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes. We are advancing a pipeline of small molecule therapeutics in orphan diseases and immunological conditions, targeting solute carriers, inflammasome complexes and GPCRs.

Read More About Our Pipeline


Together we are discovering new drugs to treat orphan or immunological disease

We are headquartered at our flagship site in Oxford, UK and are well-financed and backed by a top-tier investor syndicate. Find out more about life at OMass and current vacancies.

Join Us